Please Wait
Applying Filters...
menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Zanubrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 48,900Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sellas Reports Positive Ph 2a Data For SLS009, Zanubrutinib In DLBCL
    Sellas Reports Positive Ph 2a Data For SLS009, Zanubrutinib In DLBCL

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/20/3029678/0/en/SELLAS-Announces-Positive-Data-from-Phase-2a-Trial-of-SLS009-in-Combination-with-Zanubrutinib-in-DLBCL.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    Prelude Therapeutics Presents Phase 1 Results of PRT2527 Study
    Prelude Therapeutics Presents Phase 1 Results of PRT2527 Study

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/11/2995306/0/en/Prelude-Therapeutics-Presents-Preliminary-Results-of-Phase-1-Dose-escalation-Study-of-PRT2527-as-Monotherapy-and-in-Combination-with-Zanubrutinib-in-Patients-with-Relapsed-Refracto.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    BeiGene Highlights Waldenström’s Macroglobulinemia At IWWM 2024
    BeiGene Highlights Waldenström’s Macroglobulinemia At IWWM 2024

    16 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241016421498/en

    BUSINESSWIRE
    16 Oct 2024
    Share Share
    BeiGene Announces Updates to Commercial Leadership Team
    BeiGene Announces Updates to Commercial Leadership Team

    09 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240909481461/en

    BUSINESSWIRE
    09 Sep 2024
    Share Share
    BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data
    BeiGene To Present BRUKINSA Plus Venetoclax CLL SLL Data

    14 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240614058364/en

    BUSINESSWIRE
    14 Jun 2024
    Share Share
    BeiGene & NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA
    BeiGene & NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA

    13 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240613697053/en

    BUSINESSWIRE
    13 Jun 2024
    Share Share